Car-NET
Project data
Project financing: 99 175 109,82 PLN (including financing for UMED: 8 233 870,97 PLN), financed by the Medical Research Agency (ABM)
Project description:
CAR-T therapy is a significant breakthrough in medicine, but its availability in Poland is limited due to the high cost of commercial products and requirements for treatment centres.
The project aims to: 1) to optimise the therapy based on research and production in Poland, 2) to develop CAR T-cells in new indications, 3) to increase availability by reducing product costs and creating a network of competent centres, 4) to create a modern scientific and clinical base for the development of this therapy.
It is planned to launch the production of CAR T-cells at the M. Skłodowska-Curie National Institute of Oncology in Warsaw.
With the participation of all consortium partners, a centre of excellence will be created – an ‘incubator’ for scientists wishing to conduct pre-clinical and clinical research in the area of adoptive therapies. A scientific advisory board will be established to consult and provide opinions on R&D projects and to identify the optimal location for their implementation.
The project “Polish Chimeric Antigen Receptor T-cell Network” has been granted under the competition ABM/2020/4.
Beneficiary
Consortium composed of:
Medical University of Warsaw (WUM) – Leader
Partners:
- Maria Skłodowska-Curie National Institute of Oncology – National Research Institute (NIO-PIB)
- Clinical Centre of Medical University of Warsaw (UCK WUM)
- Institute of Haematology and Transfusiology (IHiT)
- Hospital of Lord’s Transfiguration of Poznan University Of Medical Sciences (SKPP)
- Antoni Jurasz University Hospital No. 1 in Bydgoszcz (SU1)
- Poznan University Of Medical Sciences (UMP)
- Pomeranian Medical University in Szczecin (PUM)
- Medical University of Łódź (UMŁ)
Coordinating Principal Investigator
prof. Sebastian Giebel, MD, PhD
UMED Site Principal Investigator
prof. Piotr Rieske, MD, PhD
prof. Wojciech Młynarski, MD, PhD